Furthermore, general questions about other drug therapy, re-hospitalizations especially in connection with atherosclerotic diseases such as cardiac death, Re-PCI, Bypass, pulmonary embolism, TIA/ stroke, bleeding, ACS/MI, and others are recorded. In this disease registry these endpoints will be recorded separately and statistically analyzed, however not defined as AE and not recorded as such. Patients will be further asked whether other adverse events occurred and whether they may be related to drug therapy. If AEs in relation to drug therapy will be reported these information will be submitted to the German health authorities. SAE, with drugs manufactured by Sanofi-Aventis,Zentiva or Genzyme will be submitted to Sanofi-Aventis.